瑞替普酶与阿替普酶在急性ST段抬高型心肌梗死溶栓治疗中的临床对比分析

Clinical effect of reteplase versus alteplase in thrombolytic therapy for acute ST-elevation myocardial infarction

目的对比分析在急性ST段抬高型心肌梗死溶栓治疗中应用瑞替普酶与阿替普酶的临床效果。方法选取我院于2015年1月至2016年1月收治的74例急性ST段抬高型心肌梗死患者,将其按照住院先后顺序分为观察组和对照组,其中观察组37例采用瑞替普酶治疗,对照组37例采用阿替普酶治疗,对比两组患者治疗效果和并发症情况。结果观察组的治疗有效率89.2%高于对照组75.7%,且观察组的并发症发生率5.4%低于对照组18.9%,差异对比均具有统计学意义(P<0.05)。结论给予急性ST段抬高型心肌梗死患者应用瑞替普酶治疗的临床效果显著,具有一定的安全性,值得临床推广和应用。

Objective To investigate the clinical effect of reteplase versus alteplase in thrombolytic therapy for acute ST-elevation myocardial infarction.Methods A total of 74 patients with acute ST-elevation myocardial infarction who were admitted to our hospital from January 2015 to January 2016 were enrolled and divided into observation group and control group according to the order of hospitalization,with 37 patients in each group.The patients in the observation group were given reteplase,and those in the control group were given alteplase.The two groups were compared in terms of clinical outcome and complications.Results Compared with the control group,the observation group had a significantly higher response rate(89.2%vs 75.7%,P<0.05)and a significantly lower incidence rate of complications(5.4%vs 18.9%,P<0.05).Conclusion Reteplase has a marked clinical effect and good safety in the treatment of patients with acute ST-elevation myocardial infarction and thus holds promise for clinical application.